Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
Hadassah Medical Organization
University Health Network, Toronto
UNC Lineberger Comprehensive Cancer Center
TCR2 Therapeutics
TCR2 Therapeutics
Herlev Hospital
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Peking University
Immatics US, Inc.
Acepodia Biotech, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Gilead Sciences
Leap Therapeutics, Inc.
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Herlev Hospital
Ludwig Institute for Cancer Research
Fudan University
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Roswell Park Cancer Institute
Shanghai 6th People's Hospital
Mie University
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Abramson Cancer Center at Penn Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Swiss Cancer Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
Zhejiang University
Mayo Clinic
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mie University
Mayo Clinic
Dana-Farber Cancer Institute